Nanosonics Ltd. engages in the provision of research, development, and commercialization of infection control and decontamination products and related technologies. The company is headquartered in Sydney, New South Wales and currently employs 466 full-time employees. The company went IPO on 2007-05-17. The firm's principal activities include the manufacturing and distribution of the trophon ultrasound probe disinfector and its associated consumables and accessories. The company is focused on the research, development, and commercialization of infection control and decontamination products and related technologies. Trophon technology includes high-frequency ultrasonic vibrations that generate a sonically activated hydrogen peroxide (H2O2) mist that kills bacteria, fungi, and viruses. Its products include trophon2, Nanosonics Auditpro, and trophon EPR. The firm's trophon2 includes AcuTrace radio frequency identification (RFID) technology, which enables digital record keeping and captures disinfection data. Nanosonics AuditPro is an automated digital system that combines clinician infection prevention decision making, with the Trophon 2 device infection control workflow data, and patient procedure information.
Follow-Up Questions
What is Nanosonics Ltd (NNCSF)'s P/E Ratio?
The P/E ratio of Nanosonics Ltd is N/A
Who is the CEO of Nanosonics Ltd?
Mr. Michael Kavanagh is the President of Nanosonics Ltd, joining the firm since 2012.
What is the price performance of NNCSF stock?
The current price of NNCSF is 2.7, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Nanosonics Ltd?
Nanosonics Ltd belongs to Health Care industry and the sector is Health Care
What is Nanosonics Ltd market cap?
Nanosonics Ltd's current market cap is $819.8
Is Nanosonics Ltd a buy, sell, or hold?
According to wall street analysts, 12 analysts have made analyst ratings for Nanosonics Ltd, including 1 strong buy, 2 buy, 5 hold, 6 sell, and 1 strong sell
